What's in a name?

Selah means that we should pause and reflect on what has been said. That definition fits nicely with the potential of the initial technologies we have licensed as well as with how Selah will conduct business.
(The word Selah occurs seventy-one times in thirty-nine of the Psalms, and three times in Habakkuk 3. For more information on the definition of Selah click here.)

Senior Management


Michael BolickMichael Bolick, President and CEO, founded Selah in May 2006. In December 2006, Michael graduated from the inaugural class of the Kauffman Foundation's FastTrac® TechVenture program at the Advanced Technology Development Center in Atlanta Georgia. Michael has more than 15 years experience in designing, building, starting up, managing and growing advanced materials manufacturing facilities. The last ten years were focused on serving the pharmaceutical industry as an executive with a Greenville based contract research and manufacturing company. Michael serves on the External Advisory Board of the University of South Carolina's NanoCenter and the Greenville Chamber's Board of Governors. Michael holds a BS Degree in Chemical Engineering from North Carolina State University.




Ken MorganKen Morgan, Chief Operating Officer, joined the Company in March 2007. With extensive senior management experience in the pharmaceutical, chemical and biotechnology industries gained during a 22 year career, Ken specializes in the areas of technology development and transfer and manufacturing design, start up and validation. Prior to joining Selah Technologies, Ken was involved with multiple startup companies developing strategic plans for commercialization of novel new technologies at the Gorlin Companies. This included evaluating investment opportunities in terms of business and technological viability. Prior to working with the Gorlin Companies, Ken was President of IRIX Manufacturing, Inc. Before that, he was the site manager for Lonza Group, Ltd. at its API facility. Ken holds a MS Degree in Chemical Engineering from the University of Alabama.




Advisory Board

Bob Strazzella

Bob has made a career advancing corporate business strategies based on achieving aggressive performance targets through internal and external growth initiatives. He has held positions of increasing domestic and international responsibility spanning a 32 year career with E.I. DuPont de Nemours. His most recent position was Group Vice President at Valeo, a global automotive components manufacturer.

Buddy Thompson

After graduating from Clemson with a BS in Chemical Engineering, Buddy spent six years working for Exxon. He then changed paths and earned a Doctor of Medicine degree from the Medical University of South Carolina. After a several year residency in ophthalmology, he established a private practice, Easley Eye Associates, in 1981. He remains a practicing Ophthalmologist, yet he also went on to become an organizing founding director of Peoples National Bank, and became involved in residential community development.

Hayne Hipp

Hayne is former CEO of The Liberty Corporation, an owner of insurance companies and television stations with additional investments in media, real estate and technology ventures. He joined Liberty in Investments in 1969, becoming Chief Executive in 1979. He is now a private investor. Hayne is a former trustee of Washington & Lee University, his alma mater and has an MBA from Wharton School at the University of Pennsylvania. He has served on numerous corporate boards and has been active in civic and non-profit organizations in South Carolina and on a national level.  In 2003 he founded Liberty Fellowship bringing together South Carolina’s young leaders with a diversity of perspectives and wide-range of thought.  Representing all segments of our state, they are working collaboratively to make South Carolina a better place for South Carolinians.

Jim Self

Jim is currently responsible for the identification and leadership of international growth and business development initiatives for Merck’s Vaccines & Infectious Disease Division. Prior to joining the MVID, Jim spent over ten years in Merck’s Corporate Development and Manufacturing Business Development groups completing transactions around the world. Jim was the Executive Director of Business Operations for the Asia Pacific Human Health Division and General Manager of Merck’s Japan Licensee business. Jim earned a BS degree in Industrial Engineering from North Carolina State University and an MBA from the Wharton School at the University of Pennsylvania.

David Cornelius

Dave has global experience including several years in Asia in commercial and business management. His most recent focus has been leading corporate wide efforts creating new growth platforms including leading a Business and Technology Incubator, New Ventures teams, and Venture Capital Investments at Dow Corning Corporation. He has experience as the CEO and Managing Director of a publically traded Australian based company. He currently leads the Growth and Innovation Group (GIG), a consultancy focused on helping organizations discover, shape and launch new growth platforms.  Dave’s education includes a BS in Chemical Engineering from Case Western Reserve, an MBA from Central Michigan University and he attended the Program for Management Development at the Harvard Business School.